Micro-cap and penny biotech stocks (those with a market cap at less than $300 million) have a reputation for being extremely speculative,...
Stroke kills an American every four minutes - more than 525,000 individuals each year - and nearly 300,000 more fall victim to its debilitating...
Gilead Sciences Inc.'s Sovaldi was a real breakthrough in the fight against the chronic liver disease hepatitis C (HCV). The condition may show no...
Biotech is in the midst of its longest bull run in history, and there's every reason to expect it will remain an attractive outperformer this...
Martin Shkreli, CEO of Turing Pharmaceuticals, made news this week when he announced he would raise the price of a medication his company had...
Over the past six months, we've seen the Nasdaq Biotechnology Index, an indicator for the entire sector, take some wild swings ...
Medical device companies can be profit-making machines - one manufacturer of magnetic resonance imaging (MRI) machines and other high-tech...
On Jan. 7, 2015, CytRX Corp. announced positive results from a study of its experimental brain cancer drug, aldoxorubicin, and...
No one is thrilled with the way new drugs and medical devices come to market in the U.S. - not the biotech and pharmaceutical...
Weight loss is a $20 billion per year industry. Yet, it seems the more we spend on shedding pounds, the more pounds we have to...
When you're evaluating most new stocks, it makes good sense to look at technical indicators - such as price-to-earnings ratio (P/E), profit...
Antibiotic-resistant microorganisms are turning into a national medical nightmare, and the need for new, more effective...
Modern medicine, for all of its sophisticated drugs, complex gadgets, and amazing surgical procedures, rarely cures...
On August 29, 2012, shares of Keryx Biopharmaceuticals - a company focused on pharmaceutical products for...
Ask any bioscience researcher about leading trends in medical science, and at some point, you're likely to hear a lot of...
The Baby Boom generation, which includes everyone born from 1946 through 1964, is now entering retirement age (65) at a rate...
With just six months left on my 2014 bioscience "profit calendar," things are really starting to look promising for the second...
At first glance, it may seem like bioscience investing is so complicated and risky that it's hardly worth your time and money to invest, at least if...
Today I want to offer a deeper explanation of one of the very best investment tools: trailing stops. Every single one of...
In bioscience investing, binary catalysts are milestone events that signal a thumbs-up or thumbs- down for an...
